Bioventix has completed a US$1.4 million sell-down of founder’s equity
Bioventix Plc has raised funds through a sell-down of the founder’s equity.
Bioventix was founded in 2003 as a biotechnology company specializing in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics such as clinical blood testing.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker in respect of the sell-down of the founder’s equity.
Sprechen Sie mit dem Deal Team
Laptaria cu Caimac has completed an IPO
Laptaria cu Caimac has raised US$5 million through a private placement of shares on the ATS Market of BSE. The funds will be used for the development of the factory, namely, the construction of a bottle and jar washing station, utility systems and packaging storage.Mehr erfahren
Nutricare has raised US$3.1 million via an entitlement offer
Nutricare Pty Ltd has raised funds to support its growth strategy.Mehr erfahren
Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland
Alexandria Pankkiiriliike Oyj (Alexandria) has raised US$9.7 million in the course of its IPO.Mehr erfahren